Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 1;146(1):9-10.
doi: 10.5858/arpa.2021-0407-LE.

Early Antibody Temporal Responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Vaccinated Subjects Determined by the cobas 6000 Spike Assay

Hanna S Loving  1 , Paulina Stallcup  1 , Peter Burbelo  2 , Jeffrey Cohen  3 , Alan Remaley  4 , David B Sacks  1 , Roa Harb  1
Affiliations

Early Antibody Temporal Responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Vaccinated Subjects Determined by the cobas 6000 Spike Assay

Hanna S Loving et al. Arch Pathol Lab Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels following Moderna, Pfizer, or J&J vaccination. A. Anti-S and anti-N levels after Moderna and Pfizer vaccines. Squares represent specimens collected after a single shot (made distinct for anti-S only). Triangles represent specimens from participants with a history of SARS-CoV-2 infection (made distinct for anti-N only). B. Anti-S levels over days following first dose of Moderna and Pfizer. Earliest time point is at 7 days (Moderna) and the latest time point is at 84 days (Pfizer). Squares represent two specimens from the same Pfizer participant. C. Anti-S levels in specimens from the six J&J participants were measured once (P5 and P6) and over time (P1 to P4). D. Anti-S levels 12 specimens from J&J participants. Each color represents the same specimen tested with both LIPS and Roche assays. All data are plotted on a logarithmic scale. Anti-S levels are reported in U/mL (Roche) and LU (LIPS); anti-N levels are reported as a cutoff index (COI; signal sample/cutoff). Values ≥250 U/mL are assigned as 260 U/mL for easier visualization. Dashed lines represent cutoff thresholds at 0.8 U/mL (Roche anti-S), 1.0 COI (Roche anti-N), and 45000 LU (LIPS anti-S). Solid lines represent the upper limit of measurement for Roche anti-S assay (250 U/mL). COI: cutoff index; LIPS: luciferase immunoprecipitation system; LU: light units; P: participant.
See this image and copyright information in PMC

References

    1. Locht C Vaccines against COVID-19. Anaesth Crit Care Pain Med. 2020;39(6):703–705. doi:10.1016/j.accpm.2020.10.006 - DOI - PMC - PubMed
    1. Food and Drug Administration (FDA). COVID-19 Vaccines. Accessed 05/31, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise...
    1. Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis. 2020;222(2):206–213. doi:10.1093/infdis/jiaa273 - DOI - PMC - PubMed
    1. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(Rr-4):1–40. - PubMed

Substances